Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil : a multicentric retrospective study

• Autor(a) principal: Rodrigues, Ana Luiza de Melo
• Data de Publicação: 2020
• Outros Autores: Bonfim, Carmem Maria Sales, Seber, Adriana, Colturato, Vergilio Antonio Rensi, Zecchin, Victor Gottardello, Nichele, Samantha, Daudt, Liane Esteves, Fernandes, Juliana Folloni, Vieira, Ana karine, Darrigo Junior, Luiz Guilherme, Gomes, Alessandra Araujo, Arcuri, Leonardo Javier, Farias, Luana Lenzi Emilio de, Picharski, Gledson Luiz, Ribeiro, Raul Corrêa, Figueiredo, Bonald Cavalcante de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/234531
• topic: Leucemia mielóide aguda; Criança; Células-tronco hematopoéticas; Transplantes; Brasil; Pediatric acute myeloid leukemia (AML); Hematopoietic stem cell transplant (HSCT); Brazil

The survival rates of children with high-risk acute myeloid leukemia (AML) treated with hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. The corresponding rate for Brazilian children with AML who undergo HSCT is unknown. We conducted a retrospective analysis of 114 children with AML who underwent HSCT between 2008 and 2012 at institutions participating in the Brazilian Pediatric Bone Marrow Transplant Working Group. At transplant, 38% of the children were in first complete remission (CR1), 37% were in CR2, and 25% were in CR3þ or had persistent disease. The donors included 49 matched-related, 59 matched-unrelated, and six haploidentical donors. The most frequent source of cells was bone marrow (69%), followed by the umbilical cord (19%) and peripheral blood (12%). The 4-year overall survival was 47% (95% confidence interval [CI] 30%–57%), and the 4-year progression-free survival was 40% (95% CI 30%–49%). Relapse occurred in 49 patients, at a median of 122 days after HSCT. There were 65 deaths: 40 related to AML, 19 to infection, and six to graft versus host disease. In conclusion, our study suggests that HSCT outcomes for children with AML in CR1 or CR2 are acceptable and that this should be considered in the overall treatment planning for children with AML in Brazil. Therapeutic standardization through the adoption of multicentric protocols and appropriate supportive care treatment will have a significant impact on the results of HSCT for AML in Brazil and possibly in other countries with limited resources.